CodaVax-RSV / Codagenix - LARVOL DELTA

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (clinicaltrials.gov) - P1 | N=51 | Active, not recruiting | Sponsor: Codagenix, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (clinicaltrials.gov) - P1 | N=51 | Recruiting | Sponsor: Codagenix, Inc | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Apr 2025

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (clinicaltrials.gov) - P1 | N=51 | Recruiting | Sponsor: Codagenix, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (clinicaltrials.gov) - P1 | N=51 | Not yet recruiting | Sponsor: Codagenix, Inc | N=36 ➔ 51 | Trial completion date: Feb 2023 ➔ May 2024 | Trial primary completion date: Aug 2022 ➔ Nov 2023

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

"FDA Fast-Tracks Codagenix RSV Vaccine Candidate ⁦@Codagenix⁩ ⁦@russopartners⁩ https://t.co/mcIcl2EOVZ" (@davidschull)

Clinical • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Codagenix, Inc; Trial completion date: Jul 2022 ➔ Feb 2023; Initiation date: Aug 2021 ➔ Mar 2022; Trial primary completion date: Jan 2022 ➔ Aug 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Codagenix, Inc

Clinical • New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: Codagenix, Inc; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (clinicaltrials.gov) - P1; N=36; Active, not recruiting; Sponsor: Codagenix, Inc; Trial completion date: Jan 2021 ➔ May 2021; Trial primary completion date: Dec 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (clinicaltrials.gov) - P1; N=36; Active, not recruiting; Sponsor: Codagenix, Inc; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Respiratory Diseases

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Codagenix, Inc; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Codagenix, Inc; Initiation date: Mar 2020 ➔ Jul 2020

Clinical • Trial initiation date • Infectious Disease

Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Codagenix, Inc

Clinical • New P1 trial